Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis' has reported that a randomized, open-label Phase III COMFORT-II (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy) study evaluating Janus kinase (JAK) inhibitor INC424 (ruxolitinib) has met primary endpoint.
Subscribe to our email newsletter
The study result suggested that INC42 has reduced spleen size in patients with primary myelofibrosis (MF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF), when compared with best available therapy, administered at doses and schedules determined by the investigator.
Earlier, Novartis has got license for INC424 from Incyte to develop and commercialize the product outside US.
Novartis Oncology president Herve Hoppenot said they are pleased to reach this important milestone in their collaboration to develop INC424, a compound representing potential progress for patients with myelofibrosis.